The Crux of the Medicine Prices' Controversy in Pakistan.
作者信息
Lee Kah S, Shahidullah Adnan, Zaidi Syed T R, Patel Rahul P, Ming Long C, Tariq Muhammad H, Malik Obaidullah, Farrukh Muhammad J, Khan Ahmad, Yee Siew M, Khan Tahir M
机构信息
Pharmacy, School of Medicine, University of TasmaniaHobart, TAS, Australia.
Department of Pharmacy, University of PeshawarPeshawar, Pakistan.
出版信息
Front Pharmacol. 2017 Aug 2;8:504. doi: 10.3389/fphar.2017.00504. eCollection 2017.
Abstract
摘要
相似文献
1
The Crux of the Medicine Prices' Controversy in Pakistan.巴基斯坦药品价格争议的关键所在。
Front Pharmacol. 2017 Aug 2;8:504. doi: 10.3389/fphar.2017.00504. eCollection 2017.
2
Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.巴基斯坦拉合尔分部基本药物的价格、可及性和可负担性评估：使用世卫组织/卫生技术评估机构方法的横断面调查。
PLoS One. 2019 Apr 25;14(4):e0216122. doi: 10.1371/journal.pone.0216122. eCollection 2019.
3
Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States.调整卫生支出的通货膨胀率：美国卫生服务研究的措施述评。
Health Serv Res. 2018 Feb;53(1):175-196. doi: 10.1111/1475-6773.12612. Epub 2016 Nov 21.
4
Crowdsourcing healthcare costs: Opportunities and challenges for patient centered price transparency.众包医疗成本：以患者为中心的价格透明度的机遇与挑战。
Healthc (Amst). 2016 Mar;4(1):3-5. doi: 10.1016/j.hjdsi.2015.06.004. Epub 2015 Jul 2.
5
Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.评估药品价格、可及性、可负担性及价格构成要素：对马来西亚药品获取情况的影响
PLoS Med. 2007 Mar 27;4(3):e82. doi: 10.1371/journal.pmed.0040082.
6
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.30个国家丙型肝炎新药的价格、成本及可负担性：一项经济分析
PLoS Med. 2016 May 31;13(5):e1002032. doi: 10.1371/journal.pmed.1002032. eCollection 2016 May.
7
Availability of consumer prices from US hospitals for a common surgical procedure.美国医院常见手术的消费者价格信息。
JAMA Intern Med. 2013 Mar 25;173(6):427-32. doi: 10.1001/jamainternmed.2013.460.
8
Americans Support Price Shopping For Health Care, But Few Actually Seek Out Price Information.美国人支持医疗保健价格比较，但很少有人真正寻求价格信息。
Health Aff (Millwood). 2017 Aug 1;36(8):1392-1400. doi: 10.1377/hlthaff.2016.1471.
9
Strategies for price reduction of HIV medicines under a monopoly situation in Brazil.巴西垄断情况下降低艾滋病毒药物价格的策略。
Rev Saude Publica. 2015;49. doi: 10.1590/S0034-8910.2015049005459. Epub 2016 Jan 15.
10
The pros and cons of a single 'Euro-price' for drugs.药品单一“欧元价格”的利弊。
Pharmacoeconomics. 1998 Mar;13(3):271-6. doi: 10.2165/00019053-199813030-00001.
引用本文的文献
1
Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries.心力衰竭中的药物治疗差异：对10个国家指南推荐治疗的可负担性调查
ESC Heart Fail. 2023 Oct;10(5):3152-3163. doi: 10.1002/ehf2.14468. Epub 2023 Aug 30.
2
The Burden of Cancer, Government Strategic Policies, and Challenges in Pakistan: A Comprehensive Review.巴基斯坦的癌症负担、政府战略政策与挑战：全面综述
Front Nutr. 2022 Jul 22;9:940514. doi: 10.3389/fnut.2022.940514. eCollection 2022.
3
A systematic review of pharmaceutical price mark-up practice and its implementation.药品价格加成实践及其实施的系统评价。
Explor Res Clin Soc Pharm. 2021 May 6;2:100020. doi: 10.1016/j.rcsop.2021.100020. eCollection 2021 Jun.
4
Access to Insulin Products in Pakistan: A National Scale Cross-Sectional Survey on Prices, Availability, and Affordability.巴基斯坦胰岛素产品的获取情况：一项关于价格、可及性和可负担性的全国性横断面调查。
Front Pharmacol. 2022 Apr 1;13:820621. doi: 10.3389/fphar.2022.820621. eCollection 2022.
5
Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications.对发展中国家（尤其关注非洲地区）应对新冠肺炎建议使用的药品和防护设备潜在短缺及价格上涨情况的快速评估及其影响
Front Pharmacol. 2021 Jan 14;11:588106. doi: 10.3389/fphar.2020.588106. eCollection 2020.
6
Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future.亚洲国家 COVID-19 相关药品价格波动和短缺快速评估：发现和未来的公共卫生意义。
Front Public Health. 2020 Dec 14;8:585832. doi: 10.3389/fpubh.2020.585832. eCollection 2020.
7
Impact of National Drug Pricing Policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post survey study using WHO/HAI methodology.2018年国家药品定价政策对巴基斯坦拉合尔地区药品可及性的影响：一项采用世界卫生组织/卫生行动信息中心方法的前后对比调查研究
BMJ Open. 2020 Oct 8;10(10):e034720. doi: 10.1136/bmjopen-2019-034720.
8
Medicines shortages in Pakistan: a qualitative study to explore current situation, reasons and possible solutions to overcome the barriers.巴基斯坦药品短缺：一项探索现状、原因和可能解决方案以克服障碍的定性研究。
BMJ Open. 2019 Sep 4;9(9):e027028. doi: 10.1136/bmjopen-2018-027028.
9
Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan.负担得起且公平地获得补贴的门诊药品？对吉尔吉斯斯坦附加药物方案共同支付的分析。
Int J Equity Health. 2019 Jun 13;18(1):89. doi: 10.1186/s12939-019-0990-6.
10
Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.巴基斯坦拉合尔分部基本药物的价格、可及性和可负担性评估：使用世卫组织/卫生技术评估机构方法的横断面调查。
PLoS One. 2019 Apr 25;14(4):e0216122. doi: 10.1371/journal.pone.0216122. eCollection 2019.
本文引用的文献
1
Uncontrollable medicine prices in Pakistan.巴基斯坦难以控制的药品价格。
Lancet. 2016 Nov 26;388(10060):2602. doi: 10.1016/S0140-6736(16)32120-1. Epub 2016 Nov 8.
2
Access to essential medicines in Pakistan: policy and health systems research concerns.巴基斯坦基本药物的可及性：政策和卫生系统研究关注点。
PLoS One. 2013 May 22;8(5):e63515. doi: 10.1371/journal.pone.0063515. Print 2013.
3
Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.36个发展中国家和中等收入国家的药品价格、可及性及可负担性：一项二次分析
Lancet. 2009 Jan 17;373(9659):240-9. doi: 10.1016/S0140-6736(08)61762-6. Epub 2008 Nov 29.
4
The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.六个低收入和中等收入国家中某些慢性病基本药物的可获得性和可负担性。
Bull World Health Organ. 2007 Apr;85(4):279-88. doi: 10.2471/blt.06.033647.
Zotero 插件